DC
ABBV icon

Diametric Capital’s AbbVie ABBV Stock Holding History

Diametric Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,490
Closed -$312K – 317
2025
Q1 		$312K Buy
+1,490
New +$290K 0.37% 95
2019
Q4 		– Sell
-36,843
Closed -$2.75M – 125
2019
Q3 		$2.75M Buy
+36,843
New +$2.53M 2.27% 10
2018
Q1 		– Sell
-15,640
Closed -$1.51M – 84
2017
Q4 		$1.51M Buy
+15,640
New +$1.47M 0.92% 48

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Diametric Capital's ABBV Position: Q2 2025 in Review

Diametric Capital sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 1,490 shares — an estimated $312K sold.

Diametric Capital first reported a position in ABBV in Q4 2017 and held it in 3 quarters. The position peaked at $2.75M in Q3 2019. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Diametric Capital reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
  • Diametric Capital sold 1,490 AbbVie shares in Q2 2025, an estimated $312K.
  • Diametric Capital first reported a position in AbbVie in Q4 2017 and held it in 3 quarters.
  • Diametric Capital's AbbVie position peaked at $2.75M in Q3 2019.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.